We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Animal Model and Predictive Test Developed for Preeclampsia

By LabMedica International staff writers
Posted on 28 Oct 2010
Scientists have developed a well-defined animal model of preeclampsia and a potential lab test for diagnosing the disease in people. More...
Preeclampsia is a potentially dangerous condition that sometimes occurs during pregnancy and can be fatal for both mother and fetus.

The presence of the immune system secretion Interleukin-10 (IL-10) has been linked to a successful course of pregnancy. Scientists from Brown University and Women & Infants Hospital experimented with mice genetically engineered to lack IL-10. They isolated blood serum from human patients with preeclampsia, gave a dose of it to the mice, and the rodents developed preeclampsia symptoms. Further experiments with nonpregnant mice and pregnant wild mice confirmed that pregnant mice lacking IL-10 provide a unique and dependable model of the disease.

An animal model for preeclampsia will allow for experiments that help gain insight into the cause of the disease and its progression said Surendra Sharma, professor of pediatrics at the Warren Alpert Medical School of Brown University (Providence, RI, USA) and a research scientist at Women & Infants. One observation already made is that there is disruption in the development of "spiral arteries,” which bring nutrients to the fetus from the placenta.

This observation led to the development of a predictive test for preeclampsia. An in vitro culture of two key cell types involved in spiral artery development (endothelial cells and trophoblasts) was exposed to serum from women with normal pregnancies or to preeclampsia serum from women taken at various stages of their pregnancies.

Vasculature developed normally in the presence of serum from women with normal pregnancies whereas preeclampsia serum taken from women as early as 12 to 14 weeks into their pregnancies, about 10 to 12 weeks before they were diagnosed with preeclampsia, was able to disrupt vascular formation.

Prof. Sharma is continuing to refine the test for eventual clinical use.

Related Links:

Warren Alpert Medical School of Brown University



New
Gold Member
Latex Test
SLE-Latex Test
Serological Pipet Controller
PIPETBOY GENIUS
New
PlGF Test
Quidel Triage PlGF Test
New
Silver Member
Quality Control Material
Multichem ID-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: New research brings hope for improved early detection of pancreatic cancer (Photo courtesy of Adobe Stock)

New Biomarker Panel to Enable Early Detection of Pancreatic Cancer

Pancreatic cancer (PC) has one of the worst prognoses globally, with only 13% of diagnosed patients surviving for five years or more. In Ireland, there are about 900 cases of pancreatic cancer annually,... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.